Vera Therapeutics, Inc. (VERA) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Group 1 - The FDA is currently reviewing the atacicept application submitted by the company, which has been accepted with a PDUFA date set for July 7, indicating a priority review status [2] - The data package for the atacicept application appears to be straightforward, suggesting that there may not be significant issues to address during the mid-cycle review [2] - Discussion points for potential FDA focus include labeling and other review issues, indicating that the company is preparing for possible inquiries from the FDA [2]